Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giulia Benevolo

Showing results (11-20 of 122) with videos related to

Pageof 13
Sort By:
Acta Haematologica|November 8, 2018
JAK2V617F, CALR, and MPL Mutations and Bone Marrow Histology in Patients with Essential ThrombocythaemiaAchille Pich, Ludovica Riera, Paola Francia di Celle, et al.
Expert Review of Hematology|August 13, 2021
Bone marrow morphological features and therapy in patients with Philadelphia-negative neoplasmsAchille Pich, Eloise Beggiato, Laura Godio, et al.
British Journal of Haematology|September 8, 2015
Novel CALR somatic mutations in essential thrombocythaemiaLudovica Riera, Simona Osella-Abate, Giulia Benevolo, et al.
Hematological Oncology|September 8, 2018
Diagnostic framing of IgM monoclonal gammopathy: Focus on Waldenström macroglobulinemiaAlessandra Tedeschi, Concetta Conticello, Rita Rizzi, et al.
British Journal of Haematology|October 29, 2015
Safety and efficacy of ruxolitinib in myelofibrosis patients without splenomegalyFrancesca Palandri, Nicola Polverelli, Massimo Breccia, et al.
Vascular Health and Risk Management|November 29, 2023
Diagnosis and Management of Cardiovascular Risk in Patients with Polycythemia VeraGiulia Benevolo, Monia Marchetti, Remo Melchio, et al.
Annals of Hematology|February 23, 2018
Identification and assessment of frailty in older patients with chronic myeloid leukemia and myelofibrosis, and indications for tyrosine kinase inhibitor treatmentMassimo Breccia, Francesca Palandri, Luigiana Luciano, et al.
Journal of Hematology & Oncology|January 15, 2017
Can pegylated interferon improve the outcome of polycythemia vera patients?Elena Crisà, Marco Cerrano, Eloise Beggiato, et al.
Cancer|April 22, 2011
The efficacy and safety of bortezomib and dexamethasone as a maintenance therapy in patients with advanced multiple myeloma who are responsive to salvage bortezomib-containing regimensGiulia Benevolo, Alessandra Larocca, Massimo Gentile, et al.
Journal of Hematology & Oncology|September 26, 2018
A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosisStephen Couban, Giulia Benevolo, William Donnellan, et al.
Pageof 13

Showing results (11-20 of 122) with videos related to

Sort By:
Pageof 13
Acta Haematologica|November 8, 2018
JAK2V617F, CALR, and MPL Mutations and Bone Marrow Histology in Patients with Essential ThrombocythaemiaAchille Pich, Ludovica Riera, Paola Francia di Celle, et al.
Expert Review of Hematology|August 13, 2021
Bone marrow morphological features and therapy in patients with Philadelphia-negative neoplasmsAchille Pich, Eloise Beggiato, Laura Godio, et al.
British Journal of Haematology|September 8, 2015
Novel CALR somatic mutations in essential thrombocythaemiaLudovica Riera, Simona Osella-Abate, Giulia Benevolo, et al.
Hematological Oncology|September 8, 2018
Diagnostic framing of IgM monoclonal gammopathy: Focus on Waldenström macroglobulinemiaAlessandra Tedeschi, Concetta Conticello, Rita Rizzi, et al.
British Journal of Haematology|October 29, 2015
Safety and efficacy of ruxolitinib in myelofibrosis patients without splenomegalyFrancesca Palandri, Nicola Polverelli, Massimo Breccia, et al.
Vascular Health and Risk Management|November 29, 2023
Diagnosis and Management of Cardiovascular Risk in Patients with Polycythemia VeraGiulia Benevolo, Monia Marchetti, Remo Melchio, et al.
Annals of Hematology|February 23, 2018
Identification and assessment of frailty in older patients with chronic myeloid leukemia and myelofibrosis, and indications for tyrosine kinase inhibitor treatmentMassimo Breccia, Francesca Palandri, Luigiana Luciano, et al.
Journal of Hematology & Oncology|January 15, 2017
Can pegylated interferon improve the outcome of polycythemia vera patients?Elena Crisà, Marco Cerrano, Eloise Beggiato, et al.
Cancer|April 22, 2011
The efficacy and safety of bortezomib and dexamethasone as a maintenance therapy in patients with advanced multiple myeloma who are responsive to salvage bortezomib-containing regimensGiulia Benevolo, Alessandra Larocca, Massimo Gentile, et al.
Journal of Hematology & Oncology|September 26, 2018
A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosisStephen Couban, Giulia Benevolo, William Donnellan, et al.
Pageof 13